IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing novel secretome therapeutics for age-related diseases and immune dysfunction, was recently granted permission by the FDA to proceed with its Phase II clinical trial testing its investigational secretome (IMMUNA) in reversing sarcopenic obesity.

加利福尼亚州欧文市（商业新闻短讯）--Immunis, Inc.，一家临床阶段的生物技术公司，正在开发针对年龄相关疾病和免疫功能障碍的新型分泌蛋白治疗剂，最近被FDA批准进行其II期临床试验，测试其研究性分泌蛋白（IMMUNA）逆转肌肉减少性肥胖。

The news comes shortly after Immunis completed secretome-treatment of its third patient cohort in a Phase I/IIa clinical trial for age-related muscle atrophy (sarcopenia).

这条消息是在Immunis完成其第三个患者队列的分泌蛋白治疗后不久发布的，该患者队列是针对年龄相关性肌肉萎缩（肌肉减少症）的I/IIa期临床试验。

In the U.S., obesity rates have skyrocketed within the past few decades, with a heavy impact on the elderly population. According to the National Center for Health Statistics, the percentage of obese Americans aged 65+ has doubled from about 20% to 40% for both men and women. Age-related obesity is strongly linked with additional health concerns including diabetes and muscle loss, which can have detrimental effects on quality of life..

在美国，肥胖率在过去几十年中急剧上升，对老年人口产生了严重影响。根据美国国家卫生统计中心的数据，65岁以上的肥胖美国人的比例已经翻了一番，从男性和女性的约20%增加到40%。与年龄相关的肥胖与其他健康问题密切相关，包括糖尿病和肌肉萎缩，这可能会对生活质量产生不利影响。。

Recently, GLP-1 drugs have become popularized by celebrities and those looking for a “quick fix” to managing weight problems, but questions remain regarding their long-term effects on health. Scientific publications reported that about 20-50% of the total weight lost from these drugs is attributed to a decrease in muscle mass, not fat.

最近，GLP-1药物已被名人和那些寻求“快速解决”体重问题的人普及，但关于其对健康的长期影响仍存在问题。科学出版物报道，这些药物减轻的总体重约有20-50%归因于肌肉质量的减少，而不是脂肪的减少。

This means that individuals who take GLP-1s over an extended period may experience a decline in muscle size and function over time. This is an area of concern as muscle loss is associated with an increase in falls, fractures, and comorbidities, accounting for more than $40 billion in annual health care costs in the U.S. alone.

这意味着长期服用GLP-1的人可能会随着时间的推移肌肉大小和功能下降。这是一个值得关注的领域，因为肌肉损失与跌倒、骨折和合并症的增加有关，仅在美国，每年的医疗保健费用就超过400亿美元。

Immunis is seeking to change this outcome with its investigational secretome, IMMUNA, which can reduce fat, while preserving muscle. This year, Immunis published preclinical data in Aging Cell supporting that IMMUNA increases whole-body lean mass and reduces fat mass, while increasing muscle size, enhancing muscle regeneration, and improving muscle function.

Immunis正在寻求通过其研究性分泌蛋白组IMMUNA来改变这一结果，IMMUNA可以减少脂肪，同时保留肌肉。今年，Immunis在《衰老细胞》杂志上发表了临床前数据，支持IMMUNA增加全身瘦肉量并减少脂肪量，同时增加肌肉大小，增强肌肉再生并改善肌肉功能。

Immunis’ Phase I/IIa results demonstrate no adverse events attributable to drug, with a strong suggestion of enhanced muscle function resulting in an increased quality of life measurement, the 6-minute walk test. Immunis will conduct a follow-up Phase II clinical trial to test the efficacy of IMMUNA in combating sarcopenic obesity, in the hopes of increasing mobility and independence..

Immunis的I/IIa期结果表明，没有药物引起的不良事件，强烈建议增强肌肉功能，从而提高生活质量，即6分钟步行测试。Immunis将进行一项后续的II期临床试验，以测试IMMUNA在对抗肌肉减少性肥胖方面的功效，以期提高移动性和独立性。。

“Our innovative therapy shows promising results by simultaneously decreasing fat and enhancing muscle and muscle function. We're taking a significant stride towards improving healthspan,' explains Dr. Hans Keirstead, Chairman of Immunis.

Immunis董事长汉斯·凯尔斯特德（Hans Keirstead）博士解释说：“我们的创新疗法通过同时减少脂肪和增强肌肉和肌肉功能显示出有希望的结果。我们正在朝着改善健康跨度迈出重要的一步。”。

About Immunis Inc.

关于Immunis Inc。

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations.

Immunis是一家私营生物技术公司，开发了一种新型免疫调节分泌蛋白产品，用于治疗年龄和疾病相关免疫衰退的各种表现。研究产品线利用Immunis在分泌组技术方面的领先能力，以天然相对生理浓度提供全天然，全人类免疫调节剂的产品。